TQ05105
Phase 2Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQ05105 is one of 63 small molecule programs targeting Chronic Graft Versus Host Disease. It is currently in Phase 2.
2
Indications
14
Total Trials
5
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in Myelofibrosis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Ojjaara
GGlaxo Dba Glaxosmithkline
Approved
Tepadina
Jazz PharmaceuticalsApproved
Rifadin
SanofiApproved
Droxia
TTheravia
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Vonjo
SSobi, Inc.
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Navitoclax
AbbViePhase 3
Rytelo
GGeron Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelofibrosis4 trials
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05020652·107 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05020652·107 enrolledChronic Graft Versus Host Disease2 trials
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04944043·45 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04944043·45 enrolledMyeloproliferative Neoplasms1 trial
Hepatic Impairment1 trial
5 more indications
Renal Impairment1 trial
Acute Graft Versus Host Disease1 trial
Histiocytosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQ05105. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details